|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5-6
|
|
pubmed:dateCreated |
2001-12-13
|
|
pubmed:abstractText |
The recombinant Mycobacterium bovis BCG (rBCG) vector-based vaccine secreting the V3 principal neutralizing epitope of human immunodeficiency virus type 1 (HIV-1) Japanese strain was reported to induce both humoral and cellular immune responses effectively [Proc. Natl. Acad. Sci. USA. 92 (1995) 10693]. The antigen-secreting rBCG system was applied to the V3 epitope of clade E HIV-1 in this study. The V3 sequence of 19 amino acids (aa) and 15aa fused with mycobacterial alpha-antigen was not secreted while 12aa and 11aa sequences were successfully secreted from BCG cells. Serum IgG from guinea pig which was immunized with 12aa epitope-secreting recombinant BCG neutralized the WHO reference strain as well as primary field isolates of clade E virus. The serum IgG could also neutralize Thai B (clade B') strains which possessed a conserved GPGQ motif in their V3 sequences. These data suggest that the rBCG construct secreting the 12aa epitope is implicated in the development of a prophylactic vaccine in Thailand in which both clade E and B' viruses are prevalent.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
pubmed-author:ChujohYY,
pubmed-author:HagaSS,
pubmed-author:HondaMM,
pubmed-author:MatsuiAA,
pubmed-author:NaganawaSS,
pubmed-author:NakasatomiTT,
pubmed-author:OkamotoYY,
pubmed-author:SomeyaKK,
pubmed-author:YamazakiAA,
pubmed-author:YamazakiSS,
pubmed-author:YoshikuraHH,
pubmed-author:YoshizakiHH
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
12
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
797-804
|
|
pubmed:dateRevised |
2006-4-21
|
|
pubmed:meshHeading |
pubmed-meshheading:11738743-AIDS Vaccines,
pubmed-meshheading:11738743-Amino Acid Sequence,
pubmed-meshheading:11738743-Animals,
pubmed-meshheading:11738743-BCG Vaccine,
pubmed-meshheading:11738743-Epitopes,
pubmed-meshheading:11738743-Genetic Vectors,
pubmed-meshheading:11738743-Guinea Pigs,
pubmed-meshheading:11738743-HIV Antibodies,
pubmed-meshheading:11738743-HIV Envelope Protein gp120,
pubmed-meshheading:11738743-HIV Infections,
pubmed-meshheading:11738743-HIV-1,
pubmed-meshheading:11738743-Humans,
pubmed-meshheading:11738743-Molecular Sequence Data,
pubmed-meshheading:11738743-Mycobacterium bovis,
pubmed-meshheading:11738743-Neutralization Tests,
pubmed-meshheading:11738743-Peptide Fragments,
pubmed-meshheading:11738743-Thailand,
pubmed-meshheading:11738743-Vaccines, Synthetic
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine.
|
|
pubmed:affiliation |
Central Research Laboratories, Ajinomoto Co., Inc., Suzuki-cho 1-1, Kawasaki-ku, Kawasaki 210-0801, Japan.
|
|
pubmed:publicationType |
Journal Article
|
